Vitamin k, warfarin and prothrombin: an alternate pathway to improve cancer survival


Published: June 3, 2009
Abstract Views: 149
PDF: 216
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

Billroth first proposed a theoretical relationship between hemostatic mechanisms and the development of cancer metastasis in 1878. A lack of experimental animal models to study cancer metastasis inhibited further studies on hemostasis and cancer until the late 1960s and early 1970s.1 Since that time, studies using mouse and rat models, have demonstrated a reduction of tumor metastasis and improved animal survival with systemic anticoagulation. However, the therapeutic benefits observed in these models cannot be attributed to a single, specific intervention in the coagulation system since a variety of anticoagulants, anti-platelet and fibrinolytic agents appeared to be effective.1

Supporting Agencies


Liebman, H. (2009). Vitamin k, warfarin and prothrombin: an alternate pathway to improve cancer survival. Hematology Meeting Reports (formerly Haematologica Reports), 1(9). https://doi.org/10.4081/hmr.v1i9.321

Downloads

Citations